ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities.
The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023. [1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030, [2] these efforts aim to better position Singapore-based innovations to scale and enter new markets.
Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem.
The partnership will focus on several key areas:
"This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success.
"A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore."
About ClavystBio
ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology.
Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg
About Diagnostics Development Hub (DxD Hub)
The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit www.a-star.edu.sg/dxdhub
About MedTech Catapult
MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
MTCM Securitization Architects Partners with Tokeny to Launch Dual-Format Issuance Framework Bridging Traditional and Digital Securities
LUXEMBOURG, June 23, 2025 /PRNewswire/ -- MTCM, a Luxembourg-based securitization platform serving clients across Europe ( the Americas, MENA, and Asia, has entered into a strategic partnership with Tokeny, the leading onchain operating system, to enable the issuance of both traditional and digital securities through a unified workflow. This collaboration marks the launch of the first dual-format issuance framework in Luxembourg, where an ISIN-listed note and a permissioned security token are minted simultaneously from the same legal compartment, ensuring full fungibility and compliance across both formats. Pedro Herranz, Managing Partner at MTCM, commenced: "The partnership with Tokeny allows us to industrialize a dual-issuance model that was previously not possible. We now produce a fungible twin issuance: one leg as an ISIN-listed note settled via a leading international CSD, the other as ERC-3643-based permissioned tokenized notes onchain. This structure enables investors and arrangers to choose between blockchain or traditional settlement, without compromising on compliance, operational efficiency, or investor protections." Luc Falempin, CEO of Tokeny, added: "The dual issuance model is a practical way to help traditional investors get familiar with the onchain format. Once they try these assets, which are faster to settle, easier to access, and enhanced with features that weren't possible before, they will naturally prefer the modernized and better way to access, manage, and transfer securities. This would definitely accelerate the demands from buy sides and drive the adoption." Under a white-label integration, Tokeny's T-REX tokenization platform has been embedded into MTCM's comprehensive end-to-end solutions. While MTCM acts as structurer, administrator and calculation agent, Tokeny provides easy-to-use interfaces to all stakeholders. The integration is now live and supports the full lifecycle of a digital issuance, from onboarding and KYC to subscription and secondary solutions, within MTCM's white-labeled investor portal. Tokeny's technology simplifies complex workflows, embedding digital identity, AML/KYC verification, wallet integration, and cap table management into a single interface, reducing onboarding friction and improving transparency for all stakeholders. This model significantly improves access, speed, and cost efficiency in structured finance. Institutional and professional investors can now self-custody digital securities, bypassing the high distribution and custodian costs typically associated with structured notes. For arrangers, this hybrid issuance opens up a wider distribution universe, combining reach through the traditional investors with new and blockchain-native investor segments. With over €2.5 billion in assets under service and a 400% increase in AUS over the past two years, MTCM continues to expand its global footprint and lead innovation in hybrid financial structuring. By merging the benefits of capital markets infrastructure with onchain efficiency, MTCM and Tokeny are redefining how structured investments are issued, distributed, and managed in a multi-rail financial future. About MTCM Founded in 2010, MTCM is a leading global securitization group with offices in Switzerland, Luxembourg, Spain, Panama, and Dubai. The firm specializes in structuring and delivering end-to-end, tailor-made securitization solutions under Luxembourg's Securitization Law. By making virtually any asset bankable and streamlining the relationship between investors and underlying exposures, MTCM empowers clients to access efficient, compliant, and scalable financing structures. The firm combines legal precision, operational agility, and deep structuring expertise to issue and manage complex financial instruments across both traditional and digital rails. As a pioneer of hybrid issuances, MTCM consistently seeks to deliver the most efficient and agile solutions by combining the strengths of traditional capital markets infrastructure with the advantages of digital technologies—offering clients seamless access to both conventional and tokenized financial instruments. At MTCM, we don't just design structures—we make things happen. About Tokeny Tokeny is a leading onchain finance platform and part of Apex Group, a global financial services provider with over 13,000 people across 112 offices in 52 countries. With seven years of proven experience, Tokeny provides financial institutions with the technical tools to represent assets on the blockchain securely and compliantly without facing complex technical hurdles. Institutions can issue, manage, and distribute securities fully onchain, benefiting from faster transfers, lower costs, and broader accessibility. Investors enjoy instant settlement, peer-to-peer transferability, and access to a growing ecosystem of tokenized assets and DeFi services. From opening new distribution channels to reducing operational friction, Tokeny enables institutions to modernize how assets move and go to market faster, without needing to be blockchain experts.
Korea Herald
12 hours ago
- Korea Herald
Posco to sell off non-core overseas units in China, Vietnam
Posco Group is fast-tracking the restructuring of its non-core subsidiaries, divesting low-performing overseas businesses as part of a broader strategy to reallocate resources toward high-potential sectors, particularly battery materials. According to industry sources on Monday, Posco International, the trading and resources arm of Posco Group, has agreed to sell its entire stake in Suzhou Pohang Steel to Guangdong Wcan Magnetic Materials. The transaction, valued in the 40 billion won ($29 million) range, is expected to close by June 30. Founded in 2005, Suzhou Pohang Steel, a China steel processing subsidiary, specializes in processing electrical steel and manufacturing motor components, supplying Posco products throughout eastern China. 'It is true that the sale is part of our ongoing restructuring efforts, but final confirmation from the buyer and specific deal terms are still being finalized,' a Posco Group official said. The decision reflects Posco International's strategic assessment that continued operations in China's oversaturated steel market are no longer necessary. Deteriorating conditions for Korean companies in China, exacerbated by rising geopolitical tensions such as US-China trade friction, also contributed to the move. In a separate deal, Posco Engineering & Construction is negotiating the sale of its Vietnamese subsidiary, Posco E&C Vietnam. Busan-based auto parts maker Seoil Casting has been selected as the preferred bidder, and discussions over detailed terms are underway. The subsidiary has been involved in various local construction projects, including steel structures and plant facilities. The deal is estimated to be worth around 17 billion won. Established in 1995 as a joint venture between Posco Construction and Vietnamese state-owned Lilama, holding 70 percent and 30 percent stakes respectively, Posco E&C Vietnam became wholly owned by Posco after it acquired Lilama's stake in 2010. However, the unit has faced persistent challenges, with reports indicating it had fallen into complete capital erosion by mid-2023. The recent moves are part of a broader restructuring initiative announced last year, under which Posco plans to liquidate or divest more than 120 underperforming or non-essential businesses by 2026. The goal is to raise some 2.6 trillion won to reinvest into its core pillars: steel and battery materials. As of the first quarter, the group had already achieved 40 percent of the target.
Korea Herald
13 hours ago
- Korea Herald
Samsung, SK hynix on edge over US chip waiver rollback
South Korean chipmakers are facing renewed uncertainty over their operations in China, as Washington reportedly considers revoking waivers that have allowed them to bring in American chip equipment for facility upgrades. Samsung Electronics and SK hynix, Korea's leading chipmakers with major semiconductor fabs in China, were reportedly notified last week that the US government plans to cancel the exemptions, according to a report by The Wall Street Journal on Saturday. The waivers had been granted under the Biden administration's export controls, which aim to prevent the shipment of advanced chip manufacturing tools — including those from Applied Materials and Lam Research — to China. To avoid disrupting global supply chains, however, the US had offered one-year waivers to major chipmakers such as Samsung Electronics, SK hynix and TSMC, allowing them to import equipment without individual licensing. In the latest development, Jeffrey Kessler, former undersecretary of commerce for industry and security during US President Donald Trump's second term, reportedly informed the firms of the government's intention to cancel the waivers. Kessler described the move as 'part of the Trump administration's crackdown on critical US technology going to China.' White House officials added that the licensing system for chip equipment could resemble China's controls on rare-earth exports. While the US has stepped up efforts in recent years to curb China's growth in the semiconductor sector, South Korean chipmakers have already taken steps to mitigate potential risks, leading to expectations of limited immediate impact. However, the companies remain on alert, as their Chinese fabs still account for a significant share of their total production. 'The US regulations are primarily intended to limit Chinese companies, not global firms, so there could be exemptions,' an industry official said. 'We are closely monitoring the situation, as no formal measure has been announced yet.' Kim Yang-paeng, a senior researcher at the Korea Institute for Industrial Economics and Trade, noted that companies have had time to prepare. 'Restrictions on expanding facilities or bringing in US-made equipment to China have long been in place,' he said. 'While the latest move may have some impact, it is not likely to pose a significant threat to Korean firms for now.' Samsung Electronics operates a NAND flash production facility in Xi'an, Shaanxi Province, and a chip packaging plant in Suzhou, Jiangsu Province. The company relies on China for roughly a quarter of its chip sales. SK hynix, which recently became the world's largest memory chip-maker, runs a DRAM fab in Wuxi, Jiangsu Province, a packaging facility in Chongqing, and a NAND flash plant in Dalian, Liaoning Province, which it acquired from Intel in 2020. According to industry sources, the company produces about 40 percent of its total DRAM output and about 30 percent of its NAND flash volume in China. Just three months ago, SK hynix completed a final payment of $2.24 billion to Intel for the Dalian facility.
